Boehringer's Giotrif to get survival benefit on EU label; BMS sells Ixempra rights; No CV trial necessary for Esperion cholesterol med;

> European regulators recommended a label update for Boehringer Ingelheim's lung cancer drug Giotrif to cite a one-year overall survival benefit in a study in patients with a certain EGFR mutation, compared with chemotherapy. Release

> R-Pharma US bought the rights to Bristol-Myers Squibb's ($BMY) breast cancer treatment Ixempra and launched U.S. commercial operations to handle the drug. Report

> The FDA decided not to require a cardiovascular outcomes trial on Esperion Therapeutics' anti-cholesterol drug ETC-1002, a drug that could eventually compete with the forthcoming PCSK9 drugs. Report

> Kantar Health teamed up with Data2Life to flag early signals on drug side effects, based on data gleaned from a variety of real-world sources. Release

> Concordia Pharmaceuticals and Par Pharmaceutical settled charges of anti-competitive behavior leveled by the Federal Trade Commission, over an agreement not to compete sell rival generic versions of the ADHD drug Kapvay. Report

> Merck & Co. recalled 276,000 bottles of its chemotherapy drug branded and generic Temodar over cracks in child-proof caps. Report

A naloxone-dispensing clinic in Northern Kentucky helped change people's minds in favor of providing the opioid-overdose drug. Report

And Finally... Anthem issued a reminder to Medicare patients to switch to 90-day prescriptions in a move to boost adherence. Report

Suggested Articles

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.